16.30
price up icon1.24%   0.20
after-market Handel nachbörslich: 16.50 0.20 +1.23%
loading
Schlusskurs vom Vortag:
$16.10
Offen:
$16.19
24-Stunden-Volumen:
912.25K
Relative Volume:
0.75
Marktkapitalisierung:
$1.82B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-11.64
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
-2.92%
1M Leistung:
-2.34%
6M Leistung:
-39.24%
1J Leistung:
-13.67%
1-Tages-Spanne:
Value
$16.01
$16.37
1-Wochen-Bereich:
Value
$15.90
$17.02
52-Wochen-Spanne:
Value
$14.17
$34.13

Novocure Ltd Stock (NVCR) Company Profile

Name
Firmenname
Novocure Ltd
Name
Telefon
44 (0)15 3475 6700
Name
Adresse
NO. 4 THE FORUM, ST. HELIER
Name
Mitarbeiter
1,488
Name
Twitter
@novocure
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
NVCR's Discussions on Twitter

Vergleichen Sie NVCR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Devices icon
NVCR
Novocure Ltd
16.30 1.87B 577.74M -149.78M -78.21M -1.40
Medical Devices icon
ABT
Abbott Laboratories
125.73 228.77B 43.11B 13.98B 6.66B 7.98
Medical Devices icon
BSX
Boston Scientific Corp
103.16 153.09B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
395.15 149.27B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
91.65 114.31B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
76.30 45.06B 5.54B 4.18B 623.10M 7.00

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-08 Eingeleitet Ladenburg Thalmann Buy
2024-12-02 Hochstufung Evercore ISI In-line → Outperform
2024-10-16 Hochstufung H.C. Wainwright Neutral → Buy
2023-11-20 Fortgesetzt JP Morgan Neutral
2023-08-28 Herabstufung H.C. Wainwright Buy → Neutral
2023-08-08 Hochstufung Piper Sandler Neutral → Overweight
2023-08-04 Eingeleitet SVB Securities Outperform
2023-07-31 Hochstufung Evercore ISI Underperform → In-line
2023-06-07 Hochstufung Wedbush Underperform → Neutral
2023-05-16 Hochstufung Wells Fargo Equal Weight → Overweight
2023-03-17 Herabstufung JP Morgan Neutral → Underweight
2023-01-06 Herabstufung Wells Fargo Overweight → Equal Weight
2023-01-05 Bestätigt H.C. Wainwright Buy
2022-11-29 Hochstufung Wells Fargo Equal Weight → Overweight
2022-10-24 Herabstufung Piper Sandler Overweight → Neutral
2022-07-05 Herabstufung Evercore ISI In-line → Underperform
2022-05-16 Eingeleitet H.C. Wainwright Buy
2022-02-08 Eingeleitet Loop Capital Buy
2022-02-02 Hochstufung Oppenheimer Perform → Outperform
2022-01-20 Hochstufung Truist Hold → Buy
2022-01-03 Hochstufung Evercore ISI Underperform → In-line
2021-07-01 Herabstufung Mizuho Buy → Neutral
2021-04-14 Herabstufung Wedbush Neutral → Underperform
2021-01-25 Bestätigt Piper Sandler Overweight
2020-09-23 Eingeleitet Northland Capital Outperform
2020-09-18 Herabstufung Wells Fargo Overweight → Equal Weight
2020-09-17 Herabstufung Truist Buy → Hold
2020-06-01 Fortgesetzt Oppenheimer Perform
2020-05-01 Herabstufung Oppenheimer Outperform → Perform
2020-04-09 Herabstufung Evercore ISI In-line → Underperform
2020-03-05 Hochstufung Wells Fargo Equal Weight → Overweight
2020-01-02 Herabstufung Evercore ISI Outperform → In-line
2019-07-29 Hochstufung SunTrust Hold → Buy
2019-07-26 Herabstufung JP Morgan Overweight → Neutral
2019-07-26 Herabstufung Wedbush Outperform → Neutral
2019-03-20 Eingeleitet SunTrust Hold
2018-11-02 Herabstufung Wells Fargo Outperform → Market Perform
2018-07-16 Eingeleitet Evercore ISI Outperform
2018-04-18 Bestätigt Mizuho Buy
2018-02-23 Bestätigt Mizuho Buy
2017-05-24 Hochstufung Wells Fargo Market Perform → Outperform
2016-07-29 Bestätigt Wedbush Outperform
2016-01-19 Eingeleitet Barclays Underweight
2015-12-02 Eingeleitet Deutsche Bank Hold
Alle ansehen

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

pulisher
Jul 20, 2025

What drives NovoCure Limited stock priceRobust investment performance - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Is NovoCure Limited a good long term investmentUnmatched market gains - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

M&T Bank Corp Sells 1,750 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

NovoCure Limited Stock Analysis and ForecastExplosive portfolio gains - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 16, 2025

How NovoCure Limited stock performs during market volatilityBreakout Level Watch - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes NovoCure Limited stock price move sharplyFree Stock Market Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why NovoCure Limited stock attracts strong analyst attentionFast Growing Stocks - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

NovoCure (NASDAQ:NVCR) shareholders are up 4.2% this past week, but still in the red over the last three years - simplywall.st

Jul 14, 2025
pulisher
Jul 14, 2025

Teacher Retirement System of Texas Buys 3,123 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

Most Volatile Stocks in the US (July 2025) - Investing.com

Jul 14, 2025
pulisher
Jul 11, 2025

NovoCure Ltd Stock Price Falls 3.41% Amid Analyst Predictions of 81.88% Upside - AInvest

Jul 11, 2025
pulisher
Jul 10, 2025

LADENBURG THALM/SH SH Initiates Coverage on NovoCure (NASDAQ:NVCR) - Defense World

Jul 10, 2025
pulisher
Jul 08, 2025

NovoCure stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Jul 08, 2025
pulisher
Jul 08, 2025

NovoCure stock initiated with Buy rating at Ladenburg Thalmann - Investing.com

Jul 08, 2025
pulisher
Jul 03, 2025

NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data - Investing.com Nigeria

Jul 03, 2025
pulisher
Jul 01, 2025

New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan

Jul 01, 2025
pulisher
Jun 30, 2025

Novocure to Present Final Secondary Endpoint Data from the Phase - GuruFocus

Jun 30, 2025
pulisher
Jun 30, 2025

NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 30, 2025
pulisher
Jun 30, 2025

Novocure to Report Second Quarter 2025 Financial Results | NVCR Stock News - GuruFocus

Jun 30, 2025
pulisher
Jun 29, 2025

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Jun 29, 2025
pulisher
Jun 27, 2025

Demystifying NovoCure: Insights From 4 Analyst Reviews - Nasdaq

Jun 27, 2025
pulisher
Jun 18, 2025

NovoCure Limited's (NASDAQ:NVCR) P/S Still Appears To Be Reasonable - simplywall.st

Jun 18, 2025
pulisher
Jun 16, 2025

Rhumbline Advisers Has $2.69 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

Jun 16, 2025
pulisher
Jun 12, 2025

Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles - Investing.com India

Jun 12, 2025
pulisher
Jun 06, 2025

NovoCure Ltd (NVCR) Shares Up 4.08% on Jun 6 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - TradingView

Jun 06, 2025
pulisher
Jun 06, 2025

Mackenzie Financial Corp Purchases Shares of 6,820 NovoCure Limited (NASDAQ:NVCR) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment - Investing.com

Jun 04, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Has $682,000 Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

NovoCure Ltd (NVCR) Shares Down 7.43% on Jun 2 - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

Novocure (NVCR) Gains Support for Future Launch from Promising T - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Novocure (NVCR) Gains Support for Future Launch from Promising Trial Outcomes | NVCR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data By Investing.com - Investing.com South Africa

Jun 02, 2025
pulisher
Jun 02, 2025

NovoCure Announces Positive Phase 3 Trial Results - TipRanks

Jun 02, 2025
pulisher
Jun 01, 2025

Novocure (NVCR) Announces Positive Phase 3 Trial Results for Pancreatic Cancer Therapy | NVCR Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Novocure announces results from Phase 3 PANOVA-3 trial - TipRanks

Jun 01, 2025
pulisher
May 31, 2025

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 - GuruFocus

May 31, 2025
pulisher
May 31, 2025

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Lelezard

May 31, 2025
pulisher
May 31, 2025

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting | NVCR Stock News - GuruFocus

May 31, 2025
pulisher
May 31, 2025

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Yahoo Finance

May 31, 2025
pulisher
May 30, 2025

NovoCure Ltd (NVCR) Shares Gap Down to $18.5801 on May 30 - GuruFocus

May 30, 2025
pulisher
May 28, 2025

Nuveen Asset Management LLC Lowers Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

May 28, 2025

Finanzdaten der Novocure Ltd-Aktie (NVCR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$285.57
price up icon 1.64%
medical_devices STE
$223.69
price up icon 0.47%
medical_devices PHG
$25.02
price up icon 1.96%
$85.12
price up icon 1.30%
$76.49
price up icon 3.14%
medical_devices EW
$76.30
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):